234 related articles for article (PubMed ID: 33529046)
1. Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?
Khurana A; Mwangi R; Nowakowski GS; Habermann TM; Ansell SM; LaPlant BR; Link BK; Cerhan JR; Maurer MJ; Witzig TE
J Clin Oncol; 2021 May; 39(15):1641-1649. PubMed ID: 33529046
[TBL] [Abstract][Full Text] [Related]
2. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.
Maurer MJ; Ghesquières H; Jais JP; Witzig TE; Haioun C; Thompson CA; Delarue R; Micallef IN; Peyrade F; Macon WR; Jo Molina T; Ketterer N; Syrbu SI; Fitoussi O; Kurtin PJ; Allmer C; Nicolas-Virelizier E; Slager SL; Habermann TM; Link BK; Salles G; Tilly H; Cerhan JR
J Clin Oncol; 2014 Apr; 32(10):1066-73. PubMed ID: 24550425
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.
Maurer MJ; Ghesquières H; Link BK; Jais JP; Habermann TM; Thompson CA; Haioun C; Allmer C; Johnston PB; Delarue R; Micallef IN; Peyrade F; Inwards DJ; Ketterer N; Farooq U; Fitoussi O; Macon WR; Molina TJ; Syrbu S; Feldman AL; Slager SL; Weiner GJ; Ansell SM; Cerhan JR; Salles GA; Witzig TE; Tilly H; Nowakowski GS
J Clin Oncol; 2018 Jun; 36(16):1603-1610. PubMed ID: 29672223
[TBL] [Abstract][Full Text] [Related]
4. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.
Thompson CA; Ghesquieres H; Maurer MJ; Cerhan JR; Biron P; Ansell SM; Chassagne-Clément C; Inwards DJ; Gargi T; Johnston PB; Nicolas-Virelizier E; Macon WR; Peix M; Micallef IN; Sebban C; Nowakowski GS; Porrata LF; Weiner GJ; Witzig TE; Habermann TM; Link BK
J Clin Oncol; 2014 Nov; 32(31):3506-12. PubMed ID: 25267745
[TBL] [Abstract][Full Text] [Related]
5. Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma.
Maurer MJ; Jakobsen LH; Mwangi R; Schmitz N; Farooq U; Flowers CR; de Nully Brown P; Thompson CA; Frederiksen H; Cunningham D; Jørgensen J; Poeschel V; Nowakowski G; Seymour JF; Merli F; Haioun C; Ghesquieres H; Ziepert M; Tilly H; Salles G; Shi Q; El-Galaly TC; Habermann TM
Am J Hematol; 2021 May; 96(5):599-605. PubMed ID: 33661547
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma.
Maurer MJ; Micallef IN; Cerhan JR; Katzmann JA; Link BK; Colgan JP; Habermann TM; Inwards DJ; Markovic SN; Ansell SM; Porrata LF; Johnston PB; Nowakowski GS; Thompson CA; Gupta M; Syrbu SI; Kurtin PJ; Macon WR; Nikcevich DA; Witzig TE
J Clin Oncol; 2011 Apr; 29(12):1620-6. PubMed ID: 21383282
[TBL] [Abstract][Full Text] [Related]
8. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Tun AM; Maliske S; Wang Y; Inwards DJ; Habermann TM; Micallef I; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Kharfan-Dabaja MA; Ansell SM; Nowakowski GS; Farooq U; Johnston PB
Transplant Cell Ther; 2022 Sep; 28(9):610-617. PubMed ID: 35752441
[TBL] [Abstract][Full Text] [Related]
9. Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression.
Tracy SI; Habermann TM; Feldman AL; Maurer MJ; Dogan A; Perepu US; Syrbu S; Ansell SM; Thompson CA; Weiner GJ; Nowakowski GS; Allmer C; Slager SL; Witzig TE; Cerhan JR; Link BK
Haematologica; 2018 Feb; 103(2):297-303. PubMed ID: 29170255
[TBL] [Abstract][Full Text] [Related]
10. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
Crump M; Neelapu SS; Farooq U; Van Den Neste E; Kuruvilla J; Westin J; Link BK; Hay A; Cerhan JR; Zhu L; Boussetta S; Feng L; Maurer MJ; Navale L; Wiezorek J; Go WY; Gisselbrecht C
Blood; 2017 Oct; 130(16):1800-1808. PubMed ID: 28774879
[TBL] [Abstract][Full Text] [Related]
11. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial.
Ferreri AJ; Sassone M; Zaja F; Re A; Spina M; Rocco AD; Fabbri A; Stelitano C; Frezzato M; Rusconi C; Zambello R; Couto S; Ren Y; Arcari A; Bertoldero G; Nonis A; Scarfò L; Calimeri T; Cecchetti C; Chiozzotto M; Govi S; Ponzoni M
Lancet Haematol; 2017 Mar; 4(3):e137-e146. PubMed ID: 28219694
[TBL] [Abstract][Full Text] [Related]
13. Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.
Ghesquieres H; Slager SL; Jardin F; Veron AS; Asmann YW; Maurer MJ; Fest T; Habermann TM; Bene MC; Novak AJ; Mareschal S; Haioun C; Lamy T; Ansell SM; Tilly H; Witzig TE; Weiner GJ; Feldman AL; Dogan A; Cunningham JM; Olswold CL; Molina TJ; Link BK; Milpied N; Cox DG; Salles GA; Cerhan JR
J Clin Oncol; 2015 Nov; 33(33):3930-7. PubMed ID: 26460308
[TBL] [Abstract][Full Text] [Related]
14. A phase III randomized controlled trial of radiation dose optimization in non-Hodgkin lymphoma-diffuse large B-cell lymphoma (DOBL study): Study protocol and design.
Goda JS; Lewis SC; Laskar S; Kannan S; Khanna N; Jain H; Bagal B; Epari S
Cancer Rep (Hoboken); 2019 Apr; 2(2):e1161. PubMed ID: 32935480
[TBL] [Abstract][Full Text] [Related]
15. Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma.
Wang Y; Link BK; Witzig TE; Maurer MJ; Allmer C; King RL; Feldman AL; Habermann TM; Ansell SM; Slager SL; Cerhan JR; Nowakowski GS
Blood; 2019 Oct; 134(16):1289-1297. PubMed ID: 31350266
[TBL] [Abstract][Full Text] [Related]
16. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
17. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG
Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model.
Chen Y; Neelapu S; Feng L; Bi W; Yang TH; Wang M; Fanale MA; Westin JR; Hagemeister FB; Fayad LE; Romaguera JE; Samaniego F; Turturro F; Fowler NH; McLaughlin P; Cabanillas F; Oki Y; Nastoupil LJ; Rodriguez A
Br J Haematol; 2016 Oct; 175(2):290-299. PubMed ID: 27448187
[TBL] [Abstract][Full Text] [Related]
19. Generalisability of Common Oncology Clinical Trial Eligibility Criteria in the Real World.
Karim S; Xu Y; Kong S; Abdel-Rahman O; Quan ML; Cheung WY
Clin Oncol (R Coll Radiol); 2019 Sep; 31(9):e160-e166. PubMed ID: 31133363
[TBL] [Abstract][Full Text] [Related]
20. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
